SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced financial ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
TipRanks on MSN
Gyre Therapeutics advances hydronidone toward China approval
Gyre Therapeutics ( ($GYRE) ) has issued an announcement. On January 5, 2026, Gyre Therapeutics announced that its majority-owned Chinese ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈